Drug Combination Details
| General Information of the Combination (ID: C36758) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | HLM006474 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | E2F3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | NOXA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H292 | CVCL_0455 | Lung mucoepidermoid carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One. 2014 May 15;9(5):e96357. | |||
